Skip to main content

Main navigation

  • Rapid Reactions
  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Main navigation

  • Rapid Reactions
  • Schizophrenia Foundations
  • Symptomatology
  • Patient Burden
  • Caregiver Perspectives
  • Psychopharmacology

Psychopharmacology

Medication in hand
Can Peripherally Restricted Anticholinergics Like Trospium Reduce Risks?
Brain image
What’s the Role of Amantadine in Anticholinergic Deprescription?
Muscarinic Agonism
CME: The Future of Schizophrenia Care: A Closer Look at the Role of Muscarinic Acetylcholine Receptor Activation
Synapse
CME: Emerging Therapeutic Targets for Schizophrenia: A Focus on Muscarinic Acetylcholine Receptor Activation
Medication in hand
Navigating the A to Z of Schizophrenia, Part 3: Novel Treatment Mechanisms
Muscarinic Agonism
Great Debates: Exploring Muscarinic Agonists in Schizophrenia Treatment
Brain receptors
Muscarinic Pathways in Schizophrenia: Unlocking New Therapeutic Targets
Neuron
CME: Meet Me at the Water Cooler: Schizophrenia
Patient and provider
End of the Anticholinergic Era? Challenging Cases in Anticholinergic Deprescribing: Real-World Scenarios (Module 4)
Patient and provider
End of the Anticholinergic Era? Deprescribing with Confidence: Strategies for Safe Medication Changes (Module 3)
Woman taking medication
End of the Anticholinergic Era? Measuring the Impact: Understanding Anticholinergic Burden (Module 2)

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Next page Next ›
  • Last page Last »
© 2026 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use Cookie Policy